<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04631055</url>
  </required_header>
  <id_info>
    <org_study_id>ACOART intracranial de novo</org_study_id>
    <nct_id>NCT04631055</nct_id>
  </id_info>
  <brief_title>ACOART Intracranial de Novo:DCB in the Treatment of Symptomatic Intracranial Atherosclerotic de Novo Stenosis</brief_title>
  <official_title>A Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Intracranial Drug-coated Balloon Catheters in the Treatment of Symptomatic Intracranial Atherosclerotic de Novo Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acotec Scientific Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Acotec Scientific Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the RCT trial is to determine whether DCB is not inferior to stent in treating&#xD;
      intracranial de novo stenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a prospective, multi-center, 1:1 randomized using paclitaxel coated balloon&#xD;
      versus stent to treat intracranial stenosis of 70-99% degree. And primary endpoint is&#xD;
      angiographic restenosis at 6 months post-procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic restenosis of the target lesion</measure>
    <time_frame>6 months post-procedure</time_frame>
    <description>angiographic restenosis measured by WASID ( Warfarin-Aspirin Symptomatic Intracranial Disease) method in core-lab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>device success rate</measure>
    <time_frame>during procedure</time_frame>
    <description>DCB: The balloon dilatation catheter was able to reach the treated lesion, successfully dilated without rupture, and successfully retreated.&#xD;
Stent: The stent enables successful arrival of the lesion and subsequent release of the stent delivery system for successful withdrawal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target vessel stroke or death event</measure>
    <time_frame>within 30 days post-procedure</time_frame>
    <description>Stroke (bleeding and ischemia) or death related to target vessels within 30 days postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target vessel ischemia stroke event</measure>
    <time_frame>between 31 days and 6 months post-procedure</time_frame>
    <description>The incidence of recurrent ischemic stroke in the target vessel supply area 31 days to 6 months postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral parenchyma hemorrhage, subarachnoid hemorrhage or intraventricular hemorrhage events</measure>
    <time_frame>between 31 days and 6 months post-procedure</time_frame>
    <description>Any parenchymal hemorrhage, subarachnoid hemorrhage, or intraventricular hemorrhage 31 days to 6 months postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target vessel death event</measure>
    <time_frame>between 31 days and 6 months post-procedure</time_frame>
    <description>Target-vessel related death 31 days to 6 months postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transient ischemic attack event</measure>
    <time_frame>transient ischemic attack event</time_frame>
    <description>transient ischemic attack event transient ischemic attack event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale score</measure>
    <time_frame>at 6 months post-procedure</time_frame>
    <description>National Institutes of Health Stroke Scale score at 6 months post-procedure(0-42,higher scores mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale score</measure>
    <time_frame>at 6 months post-procedure</time_frame>
    <description>Modified Rankin Scale score at 6 months post-procedure(0-5,higher scores mean a worse outcome)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Intracranial Atherosclerosis</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>DCB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use intracranial drug coated balloon catheter made by Acotec Scientific Co.,Ltd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stent group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>use the Intracranial Stent System made by MicroPort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug coated balloon</intervention_name>
    <description>paclitaxel coated balloon catheter for intracranial PTA treatment</description>
    <arm_group_label>DCB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>stent system</intervention_name>
    <description>The Intracranial Stent System comprises of a balloon expandable stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.The product, APOLLO™ stent system, has the indication of endovascular treatment for intracranial stenosis approved by NMPA.</description>
    <arm_group_label>Stent group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 80 years of age;&#xD;
&#xD;
          -  Patients with refractory symptomatic intracranial atherosclerotic stenosis after drug&#xD;
             therapy;&#xD;
&#xD;
          -  Patients with intracranial arterial de novo stenosis confirmed by digital subtraction&#xD;
             angiography (DSA);&#xD;
&#xD;
          -  Confirmed by DSA，the diameter of the target vessel is between 2.0mm-4.5mm ; according&#xD;
             to WASID method, the degree of stenosis of the target lesion is 70%-99%;&#xD;
&#xD;
          -  Baseline mRS score ≤2;&#xD;
&#xD;
          -  Voluntarily participate in this study and sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with stroke within 2 weeks before procedure;&#xD;
&#xD;
          -  Patients with stroke caused by perforating artery occlusion;&#xD;
&#xD;
          -  Any history of brain parenchymal or other intracranial subarachnoid, subdural or&#xD;
             extradural hemorrhage in the past 30 days;&#xD;
&#xD;
          -  Those who have received thrombolysis within 24 hours before procedure;&#xD;
&#xD;
          -  Deterioration of neurological function within 24 hours before procedure (defined as&#xD;
             NIHSS score increased by ≥ 4 points over the baseline);&#xD;
&#xD;
          -  The vascular path showed in angiography is so tortuous that it is difficult to advance&#xD;
             catheters to the target lesion or retrieve;&#xD;
&#xD;
          -  Lesions that investigators believe are not suitable for stenting;&#xD;
&#xD;
          -  Patients with thrombus in target vessel;&#xD;
&#xD;
          -  In addition to the target lesion, there are still other de novo lesion or ISR lesion&#xD;
             with more than 70% diameter stenosis in intracranial arteries that need to be treated&#xD;
             at the same time;&#xD;
&#xD;
          -  After endovascular treatment of the target lesion, there is still a stenosis of more&#xD;
             than 50% in the main blood supplying artery or an obstructive lesion in the distal&#xD;
             vessel of target lesion;&#xD;
&#xD;
          -  Major surgery (including open femoral artery, aortic or carotid artery surgery) within&#xD;
             the past 30 days or planned within 90 days;&#xD;
&#xD;
          -  Patients with renal artery, iliac artery, and coronary artery requiring simultaneous&#xD;
             intervention;&#xD;
&#xD;
          -  Combined with intracranial tumor, aneurysm or intracranial arteriovenous malformation;&#xD;
&#xD;
          -  Intracranial artery stenosis caused by non-atherosclerotic lesions, including:&#xD;
             arterial dissection, moya-moya disease, vasculitis disease, herpes zoster,&#xD;
             varicella-zoster or other viral vascular diseases, neurosyphilis, any Other&#xD;
             intracranial infections, any intracranial stenosis related to cerebrospinal fluid&#xD;
             cells, radiation-induced vascular disease, fibromuscular dysplasia, sickle cell&#xD;
             disease, neurofibromatosis, central nervous system benign vascular disease, postpartum&#xD;
             vascular disease, suspected Vasospasm, suspicious embolism recanalization, etc.;&#xD;
&#xD;
          -  Cardiac stroke or potential cardiogenic thromboembolism, with any of the following&#xD;
             cardiogenic embolism causes: chronic or paroxysmal atrial fibrillation, mitral valve&#xD;
             stenosis, mechanical valves, endocarditis, intracardiac thrombus or implant, dilated&#xD;
             cardiomyopathy, spontaneous acoustic imaging of the left atrium;&#xD;
&#xD;
          -  Patients with myocardial infarction within 6 weeks before procedure;&#xD;
&#xD;
          -  Those who cannot tolerate general anesthesia due to insufficiency of important organs&#xD;
             such as heart and lungs;&#xD;
&#xD;
          -  Patients with known severe hepatic and renal dysfunction;&#xD;
&#xD;
          -  Patients with hemoglobin&lt;100g/L, platelet count&lt;100×1,000,000,000/L, INR&gt;1.5 or there&#xD;
             are uncorrectable factors leading to bleeding(if there are multiple checks, the last&#xD;
             one shall prevail);&#xD;
&#xD;
          -  Patients who cannot receive dual antiplatelet therapy due to existing diseases or are&#xD;
             tolerant to dual antiplatelet therapy confirmed by relevant test;&#xD;
&#xD;
          -  Patients with known severe allergies or contraindications to heparin, paclitaxel,&#xD;
             contrast agents and other related intravascular treatment drugs;&#xD;
&#xD;
          -  Current alcohol or drug abuse, uncontrolled severe hypertension (systolic blood&#xD;
             pressure&gt;180mmHg or diastolic blood pressure&gt;110mmHg);&#xD;
&#xD;
          -  Life expectancy &lt;1 year;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Patients who cannot complete the follow-up due to cognitive, emotional or mental&#xD;
             illness;&#xD;
&#xD;
          -  Patients who are participating in other drug/device clinical trials and have not&#xD;
             completed all follow-ups required by the programmer;&#xD;
&#xD;
          -  According to the judgement of the investigator, other situations that are not suitable&#xD;
             for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhongrong Miao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhongrong Miao, MD</last_name>
    <phone>13601243293</phone>
    <email>zhongrongm@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongrong Miao, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intracranial Atherosclerosis</keyword>
  <keyword>Stroke</keyword>
  <keyword>drug coated balloon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Arteriosclerosis</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

